British drug regulators have become the first in the world to authorize an updated version of Moderna’s COVID-19 vaccine that includes protection against the Omicron variant, which the government said would be offered to people age 50 and over starting in the fall.
In a statement Monday, the Medicines and Healthcare Regulatory Agency said it had given the green light to Moderna’s combination “bivalent” vaccine, which will be used as an adult booster shot.
Each dose of the booster shot will target both the original coronavirus and the Omicron BA.1 variant that was first detected in November. British regulators said the side effects were similar to those seen for Moderna’s original booster shot and were typically “mild and self-resolving.”
“What this [combination] vaccine gives us is a sharpened tool in our armory to help protect us against this disease as the virus continues to evolve,” said Dr. June Raine, the head of Britain’s healthcare and medicines regulator.
Get our free Coronavirus Today newsletter
Sign up for the latest news, best stories and what they mean for you, plus answers to your questions.
You may occasionally receive promotional content from the Los Angeles Times.
British Health Secretary Steve Barclay said the new shot will be part of the country’s booster program roll-out from September, based on advice from the government’s vaccine experts.
“This safe and effective vaccine will broaden immunity and potentially improve protections against some variants as we learn to live with this virus,” Barclay said.
Such an approach — combining protection against several strains of the same disease — is used with flu shots, which are adjusted each year depending on the variants that are circulating and can protect against four influenza strains.
Stephane Bancel, Moderna’s chief executive, said in a statement that it was the first regulatory authorization for a vaccine designed to fight the Omicron variant. He predicted the booster would have an “important role” to play in protecting people against COVID-19 in the winter.
On Friday, Germany’s health minister said the European Medicines Agency might clear tweaked COVID-19 boosters next month.
In June, the US Food and Drug Administration told vaccine makers that any booster shots tweaked for the fall would have to include protection against the newest Omicron subvariants, meaning BA.4 and BA.5 — not the BA.1 strain included in Moderna’s latest shot.
Last month, the FDA said it was no longer considering authorizing a second COVID-19 booster for all adults but would instead focus on revamped vaccines for the autumn that target the newest viral subvariants.
Both Moderna and Pfizer are currently brewing updated versions of their vaccine to include BA.5 in addition to the original SARS-CoV-2 virus.
According to the World Health Organization, the latest global surge of COVID-19 has been driven by the BA.5 subvariant, which accounts for about 70% of the virus samples shared with the world’s largest public virus database. BA.5 is even more infectious than the original version of Omicron and has some genetic differences that earlier vaccines might not address.
Scientists have warned that the continued evolution of the coronavirus means drugmakers will probably be one step behind in their efforts to tailor their vaccines.
“The virus is unlikely to stand still and Omicron-targeted immunity might push the virus down other evolutionary paths,” warned Jonathan Ball, a professor of virology at Britain’s University of Nottingham. Still, he said the new Moderna vaccine would probably still be protective against severe disease.
Other experts said it was still unknown how effective the new combination vaccine would be.
Beate Kampmann, director of the Vaccine Center at London’s School of Hygiene and Tropical Medicine, said the shot would most likely only offer “partial protection” against the latest Omicron variants including BA.5 since it was developed based on earlier versions of the coronavirus.
“How much difference such [combination] vaccines can actually make remains to be seen,” she said, noting that the shots have not yet been widely tested in different populations.
AP Medical Writer Lauran Neergaard contributed to this story from Washington, DC
George is Digismak’s reported cum editor with 13 years of experience in Journalism